Core Insights - Resmed Inc. reported adjusted earnings per share (EPS) of $2.81 for Q2 fiscal 2026, reflecting a 15.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 4.59% [2] - The company's total revenue for the quarter reached $1.42 billion, marking an 11% year-over-year growth, also exceeding the Zacks Consensus Estimate by 2.30% [3] Revenue Performance - Revenues from the Sleep and Breathing Health segment increased by 11.6% year over year to $1.26 billion, with Devices revenues at $726.2 million, up 8.5% [5] - The Masks and other category generated $529.7 million, up 16.1% year over year, driven by strong growth in both the U.S. and international markets [6] - The Residential Care Software segment saw a revenue increase of 6.6% year over year, totaling $166.9 million [7] Margin and Profitability - The adjusted gross profit rose 17.3% to $890.5 million, with an adjusted gross margin of 62.6%, reflecting a 340 basis point expansion [8] - The adjusted operating profit for the quarter was $521.2 million, up 19.6% year over year, with an adjusted operating margin of 36.6%, expanding by 263 basis points [10] Financial Position - At the end of Q2 fiscal 2026, Resmed had cash and cash equivalents of $1.42 billion, an increase from $1.38 billion at the end of Q1 [11] - The cumulative net cash provided by operating activities was $797.1 million, compared to $634.2 million in the same period last year [11] - The company paid out $88 million in dividends and repurchased 704,000 shares for $175 million during the quarter [12] Strategic Developments - Resmed received FDA clearance for its Personalized Therapy Comfort Settings, marketed as Smart Comfort, aimed at enhancing CPAP comfort settings and improving patient adherence [15] - The performance of the Residential Care Software segment is bolstered by contributions from the Medifox DAN software vertical, targeting sustainable growth [14]

Becton Dickinson and Company (NYSE:BDX) will release earnings for its first quarter before the opening bell on Monday, Feb. 9.Analysts expect the company to report quarterly earnings of $2.81 per share. That’s down from $3.43 per share in the year-ago period. The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion (it reported $5.17 billion last year), according to Benzinga Pro.According to recent news, Becton Dickinson announced on Jan. 27 a buyback plan of up to 10 million shares. ...

分组1 - Becton Dickinson is set to release its first-quarter earnings on February 9, with expected earnings of $2.81 per share, down from $3.43 per share in the same period last year [1] - The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion, slightly lower than the $5.17 billion reported last year [1] - The company announced a buyback plan of up to 10 million shares on January 27, which has attracted investor interest in its dividends [2] 分组2 - Becton Dickinson currently has an annual dividend yield of 2.03%, with a quarterly dividend of $1.05 per share, totaling $4.20 annually [2] - To earn $500 monthly from dividends, an investment of approximately $295,103 or around 1,429 shares is required, while $100 monthly would need about $59,062 or 286 shares [2] - The dividend yield can fluctuate based on changes in the stock price and dividend payments, impacting the overall yield [3][5]

Core Insights - Edwards Lifesciences and Boston Scientific both demonstrated strong quarterly performance, indicating robust demand in the heart device market [1] Company Strategies - Edwards Lifesciences and Boston Scientific are employing fundamentally different strategies within the heart device sector, which may impact their future growth trajectories [1]

Core Insights - Abbott presented new clinical data at the AF Symposium demonstrating the safety and efficacy of its ablation catheters for treating atrial fibrillation (AFib) [1] Group 1: Volt PFA System - The Volt Pulsed Field Ablation (PFA) System achieved an industry-leading success rate of 84.2% for freedom from documented rhythm recurrence in paroxysmal AFib patients over 12 months [1] - Nearly 68% of patients with persistent AFib remained free from additional episodes after treatment with the Volt PFA System [1] - Patients reported significant improvements in quality-of-life scores, increasing from 63.6 to 91.4 for paroxysmal AFib patients and from 64.2 to 91.4 for persistent AFib patients [1] - The trial reported less than 6% of patients required repeat ablation, one of the lowest rates in the industry [1] - Physicians used an average of 4.6 therapy applications per vein, fewer than other competitive PFA systems [1] Group 2: TactiFlex Duo Ablation Catheter - The TactiFlex Duo Ablation Catheter demonstrated a clinically meaningful success rate of 81% for freedom from documented rhythm recurrence among paroxysmal AFib patients in the FOCALFLEX Global CE Mark trial [1] - Patient self-reported quality-of-life scores increased from 64.4 to 86.4 [1] - TactiFlex Duo is designed for focal ablation using a dual-energy platform, allowing tailored AFib therapy delivery [1] - The device received CE Mark approval, and the FDA granted Breakthrough Device Designation for treating Ventricular Tachycardia using PFA [1] Group 3: Market Position and Future Outlook - Abbott's Volt PFA System and TactiFlex Duo are positioned to empower physicians in treating a wide range of AFib cases, from newly diagnosed to complex cases [1] - The company aims to challenge the status quo in AFib treatment by developing better tools for physicians [1]

Core Insights - The global medical devices market is projected to grow from US$ 517.86 billion in 2024 to US$ 905.56 billion by 2033, with a CAGR of 6.4% from 2025 to 2033 [1][2] Market Growth Drivers - The market is experiencing dynamic growth due to increased focus on personalized care and early diagnostics, with significant investments in wearable sensors, robotic surgery systems, and advanced imaging tools [2] - The proliferation of digitally connected devices is evident, with an estimated 504 million wearable health monitors expected to ship worldwide in 2023 [2][4] - The US FDA granted clearances to over 2,900 novel medical technologies in the past year, indicating a strong innovation pipeline [2][4] Regional Insights - The United States, Germany, and China dominate global production, with the US having over 6,500 licensed device manufacturers in 2023 [3] - Germany exported advanced surgical instruments worth nearly US$ 28 billion last year, while China's output of single-use medical devices reached 65 billion units [3] - Asia Pacific is expected to register the highest growth rate of 7.1%, driven by strong manufacturing bases and supportive government policies [9][10] Product Innovations - Wearable healthcare solutions are redefining chronic condition management, with 504 million wearable shipments in 2023, including devices for heart rate tracking and continuous glucose monitoring [4] - The introduction of 1,200 new smartphone-linked ECG patches this year enhances diagnostic precision for cardiologists [4] - Over 40 new remote patient monitoring devices achieved CE Mark approval in Europe in the first half of 2023, reflecting robust acceptance of telemedicine solutions [8] Market Segmentation - Key product categories include diagnostic devices, patient monitoring devices, imaging systems, and consumables [12][13] - Major applications span across cardiology, orthopedics, oncology, and respiratory care [15][16] Major Players - Notable companies in the medical devices market include 3M Co., Abbott Laboratories, Johnson & Johnson, Medtronic Inc., and Siemens Healthcare [11]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3].

Company Overview - Teleflex is a diversified medical device company specializing in devices for critical care and surgical procedures, with a global presence and a broad portfolio of proprietary products [6] - The company generates revenue primarily through the design, manufacturing, and global distribution of proprietary medical devices used in hospitals and healthcare settings [8] - Key product lines include Arrow catheters, UroLift System, and vascular closure devices, addressing the needs of hospitals and healthcare providers [8] Financial Performance - As of February 4, Teleflex shares were priced at $106.00, down 38.7% over the past year, underperforming the S&P 500's roughly 14% gain in the same period [3] - Teleflex posted GAAP revenue of $913 million in the most recent quarter, reflecting a year-over-year increase of 19.4%, with adjusted diluted EPS rising to $3.67 [10] - The company has narrowed its full-year revenue guidance and lifted adjusted EPS expectations to a range of $14.00 to $14.20 [10] Investment Position - Tejara Capital Ltd increased its stake in Teleflex by 69,700 shares, with an estimated transaction value of approximately $8.45 million [2] - This acquisition raised Teleflex's stake to 2.23% of Tejara's 13F assets under management as of December 31 [3] - The total position value in Teleflex rose by $8.50 million quarter over quarter, including share additions and price fluctuations [2] Market Context - Teleflex is undergoing a transition that has impacted its stock price, which is down nearly 39% over the past year despite ongoing operating growth [9] - The company's focus on single-use medical devices and recurring hospital demand provides a different risk profile compared to Tejara's other higher-beta positions in energy, shipping, and biotech [11]

Market Overview - The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033 [1][20] - The U.S. Surgical Staplers Market is valued at USD 2.03 billion in 2025 and is projected to reach USD 3.19 billion by 2033, growing at a CAGR of 5.82% [4][20] Growth Drivers - The global burden of chronic diseases requiring surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive surgeries are driving market growth [1] - Over 310 million major surgical procedures are performed globally each year, with a significant portion being minimally invasive, increasing demand for advanced stapling devices [2] - High surgical volumes, rapid adoption of robotic-assisted surgeries, and strong hospital capital expenditure are contributing to growth in the U.S. market [4] Product Segmentation - Manual Surgical Staplers held the largest market share of 58.72% in 2025, while Powered Surgical Staplers are expected to grow at the fastest CAGR of 9.62% during 2026-2033 [9] - Disposable Surgical Staplers dominated with a 63.15% share in 2025, while Reusable Surgical Staplers are projected to expand at a CAGR of 9.47% [10] - Abdominal & Pelvic Surgery accounted for the highest market share of 35.88% in 2025, with Cardiac & Thoracic Surgery anticipated to record the fastest CAGR of 9.84% [11] End-User Insights - Hospitals & Clinics held the largest share of 71.42% in 2025, while Diagnostic Centers are expected to grow at the fastest CAGR of 9.75% during 2026-2033 [12] Regional Insights - North America had the largest market share of 42.58% due to the high number of surgeries and the use of modern stapling technology [15] - The Asia Pacific region is projected to be the fastest-growing, expanding at a CAGR of 8.34% during 2026-2033, driven by rising surgical procedures and healthcare infrastructure [16] Technological Advancements - The use of powered staplers reduces variability of manual force by over 40%, improving surgeon ergonomics and surgical outcomes [5] - Recent product launches include Ethicon's ETHICON4000 Stapler and Medtronic's enhanced Signia™ Stapling System, which feature advanced technologies for improved precision and efficiency [21]

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national in-pharmacy marketing campaign to put its products ...